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‘Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survi-
vorship (PROFILES)’ is a registry for the study of the physical and psychosocial impact of
cancer and its treatment from a dynamic, growing population-based cohort of both short
and long-term cancer survivors. PROFILES contains a large web-based component and
are linked directly to clinical data from the population-based Eindhoven cancer registry.
This paper describes the rationale and design of PROFILES.
The primary aims of studies that use the PROFILES registry are: (1) psychosocial risk and
outcome assessment to identify patients at high risk for poor physical and mental health
outcomes, (2) to analyse mediating mechanisms to better understand the biological and
behavioural factors associated with cancer treatment outcomes, and (3) to evaluate phys-
ical and psychosocial care needs of cancer survivors.
PROFILES is a tool that enables data collection management; from inviting patients to par-
ticipation in studies, to collecting patient-reported outcomes data via web-based or mailed
questionnaires and linking these data with clinical data. The availability of a control cohort
of approximately 2000 persons from the general population who complete the same basic
questionnaire annually will provide the opportunity to estimate the unique impact of can-
cer, beyond that of normal ageing and comorbidities. Raw data from the PROFILES registry
will be available for non-commercial scientific research, subject to study question, privacy
and confidentiality restrictions, and registration (www.profilesregistry.nl).
 2011 Elsevier Ltd. Open access under the Elsevier OA license.partment of Medical Psychology and Neuropsychology, Tilburg University, P.O. Box 90153,
y.edu, F.Mols@UvT.nl (F. Mols).
the Elsevier OA license.
E U R O P E A N J O U R N A L O F C A N C E R 4 7 ( 2 0 1 1 ) 2 1 8 8 –2 1 9 4 21891. Introduction form of data collection proved to be feasible, it was alsoCancer is viewed as a chronic disease for an increasing por-
tion of cancer patients. Due to increasing incidence rates, ear-
lier diagnosis and improved treatments, the number of cancer
survivors is rising rapidly in the Western world. In the year
2000, there were approximately 400,000 cancer survivors in
the Netherlands; this is expected to increase to 700,000 in
2015.1 The majority of these survivors will be relatively
long-term (>5 years after diagnosis).
The evaluation of new treatments and care protocols for
cancer patients is traditionally focused on biological out-
comes, specifically disease-free and overall or relative sur-
vival. However, today health-related quality of life (HRQoL)
is also recognised to be important, especially since many
new therapies have only a marginal impact on survival rates,
and many survivors face continuing physical and psychoso-
cial problems after completion of primary treatment. Achiev-
ing and maintaining optimal well-being is an important
objective of current cancer treatment and of cancer rehabili-
tation and aftercare.
There is a growing body of literature on cancer survivor-
ship, but the majority of studies to date have focused on a
few major diagnostic groups (e.g. breast and prostate cancer)
or have used cross-sectional designs; longitudinal data are
less readily available.2–4 Also, most studies have focussed on
the HRQoL impact of the primary diagnosis and treatment;
less attention has been paid to the HRQoL across the whole
cancer continuum.5
A recent policy report from the Health Council of the Neth-
erlands about desirability of and evidence for follow-up in
oncology concluded that there is a strong need for specific re-
search into the late (side) effects of cancer treatments, includ-
ing their psychosocial impact.6 Such studies have often
focused on selected populations or convenience samples. To
broaden this research area, the Health Council has recom-
mended that an infrastructure be created that will facilitate
the on-going evaluation of the short- and long-term effects
of new cancer therapies.6 This will provide information useful
in improving current treatment and follow-up strategies, and
stimulating future survivorship research. The availability of
health outcomes or patient-reported outcomes (PROs) regis-
tries that can be linked with cancer registries is very impor-
tant in achieving these goals.7
The Eindhoven Cancer Registry (ECR) compiles clinical
data of all individuals newly diagnosed with cancer in the
southern part of the Netherlands, an area with 10 hospitals
serving 2.3 million inhabitants.8 On a daily basis, cancer reg-
istration clerks register newly diagnosed cancer patients in
the ECR since 55 years. Over the past 35 years, this registry
has provided clinicians and researchers with a wealth of clin-
ical data (e.g. stage and primary treatment) on cancer patients
of all ages. However, data on PROs have not been available in
the ECR as in any other cancer registry. In the past 10 years,
several studies have, therefore, been set up among currently
>10,000 cancer survivors to add PROs to this clinical data-
base.9–21 PROs were collected using paper-and-pencil ques-
tionnaires, with response rates of 75–80%. Although thistime-consuming and expensive, especially in longitudinal
projects with repeated assessments of large cohorts of cancer
survivors.
The high penetration rate of internet access in the Nether-
lands (88.6% in 2010),22 and more specifically, among cancer
survivors in the ECR18 makes it feasible to develop a web-
based registry. Online administration of questionnaires has
a number of advantages compared to paper-and-pencil ques-
tionnaires, including convenience for the participant, poten-
tially large cost savings, efficiency in data collection, and
high quality of the data. Therefore, we have developed a reg-
istry, including a large web-based component, for the collec-
tion of longitudinal data on the physical and psychosocial
impact of cancer and its treatment. This PROFILES (‘Patient
Reported Outcomes Following Initial treatment and Long
term Evaluation of Survivorship’) registry is linked to the
ECR, thus allowing merging of PRO and clinical data and dis-
cussion of the results with the various clinical groups at the
CCC South. This paper describes the rationale and design of
the PROFILES registry.
2. Objectives for PROFILES
PROFILES is a web-based registry which can be used to facili-
tate data collection on PROs from cancer survivors. It can be
used simultaneously for multiple studies with different pur-
poses. The main objectives of PROFILES are to generate data
relevant to:
– Psychosocial risk and outcome assessment to identify
patients at high risk for poor health outcomes. Relevant
questions include: Which factors are associated with ongo-
ing health concerns of cancer survivors? Which patients are
in need of (psychosocial) support? Do new systemic treat-
ments, especially the new targeted ones, have a beneficial
or adverse impact on PROs (e.g. HRQL, disease-specific com-
plaints, anxiety, depression and fatigue)?
– To analyse mediating mechanisms to better understand the
biological and behavioural factors associated with cancer
treatment outcomes. For example, what is the impact of
co-morbidity on PROs in cancer survivors?
– To evaluate physical and psychosocial care (needs) of can-
cer survivors. For example, does information disclosure
relate to satisfaction with care, and health-care utilisation?
3. Relevance and limitations of PROFILES
PROFILES has a number of advantages when collecting data
on PROs. The linkage of PROs to details of patients’ diagnosis
and initial cancer treatment already available through the
ECR provides a unique monitoring system for outcome
assessment. This linkage makes it possible to interpret psy-
chosocial outcomes in relation to medical and demographic
characteristics. Additional characteristics of PROFILES that
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and international studies are: (1) the availability of more than
10,000 newly diagnosed cancer patients each year who poten-
tially can be invited to provide PRO data; (2) the high partici-
pation rate of the physicians in the ECR area; and (3) the
high response rates from cancer survivors, in combination
with the high penetration rate (89%) of internet access in
the Netherlands.22 This facilitates efficient data collection,
particularly in longitudinal panel studies. Internet-based sur-
veys can also improve the quality and completeness of data
collection.
We recognise several possible limitations to the approach
taken in developing PROFILES. First, use of internet is inver-
sely related to age. Thus, although internet penetration is
high in the Netherlands,22 it is likely that participants who
complete online questionnaires tend to be younger and have
a higher socio-economic status. To minimise this potential
bias, PROFILES continues to make use of traditional, paper-
and-pencil data collection methods in situations where inter-
net access poses difficulties. Sociodemographic and clinical
differences between internet users and non-users can be
evaluated with data available from the ECR. Importantly, the
available evidence suggests that there are few if any differ-
ences in the reliability and validity of PRO data collected on-
line versus via paper-and-pencil questionnaires.23–25 We
would note that, given current trends in the use of internet,
the percentage of patients from all age groups and socioeco-
nomic strata with access to internet will continue to increase
in the coming years.
Currently, PROFILES is a regional project and it is linked to
a regional cancer registry (the ECR) covering 2.4 million inhab-
itants that is part of the uniform national cancer registry in
the Netherlands. PROFILES can be expanded to other cancer
registries in the Netherlands or abroad. This will be important
for the study of survivors of relatively rare tumours for which
wider coverage is necessary in order to achieve sufficient sta-
tistical power.
PROFILES can be used in many ways: (1) data from PRO-
FILES can be used by clinicians and patients in deciding upon
optimal treatment that balances clinical and HRQoL effects
and outcomes. (2) Data from PROFILES can be used by health
care policy makers to identify the needs of, and to guide
health care planning for, the growing group of cancer survi-
vors; (3) it can provide information potentially helpful to pa-
tient organisations in developing services and facilities to
meet the unmet needs of cancer survivors; and (4) PROFILES
data can facilitate appropriate surveillance of those survivors
who are at high risk for late consequences of cancer treat-
ment. For example, if results show that certain subgroups
(based on tumour, gender, age, comorbidity or personality
characteristics) are at higher risk of developing psychosocial
problems in certain domains, aftercare programs can be di-
rected in a more tailored fashion.
4. Design of PROFILES
4.1. Panel management system
PROFILES consists of two components, one component for pa-
tients’ use, and one component for use by researchers. Pa-tients can visit the website (www.profielstudie.nl) to learn
more about its background, the different studies, the
researchers, recent publications, etc. This website also con-
tains a link to a secure the environment in which patients
can complete questionnaires and make changes in their per-
sonal details (e.g. an address change, preference for paper-
and-pencil questionnaires, and decision to leave the study).
The PROFILES-team uses PROFILES primarily to ‘manage’
studies with the panel management system. For example,
new samples or cohorts of patients (with additional clinical
data from the ECR) can be selected from the ECR to be included
in any given study. The system automatically produces invita-
tion letters for these patients. Also, it can be used to handle
follow-up assessments for those already participating in the
study. Since patients are also offered the possibility of com-
pleting paper-and-pencil versions of questionnaires, PROFILES
can be used to import those data (once scanned) and merge
them with web-based questionnaire data. The panel manage-
ment system offers different user levels, each with its own
function and privileges, such as researcher (to view and export
anonymous databases), data-entry employees (to register new
patients), and panel managers (access to all processes and
modules, but not the databases).
5. Inclusion of patients and normative sample
5.1. Process of patient selection and invitation
The population-based ECR offers the unique opportunity to be
used as a recruitment tool to select eligible patients for PRO
data collection. The ECR registers all newly diagnosed cancer
patients within 6 months after diagnosis. This facilitates
approaching cancer survivors for study participation soon
after their initial diagnosis and primary treatment. Also, previ-
ous survivorship studies have shown that patient selection via
the ECR works well for long-term survivors (5–15 years after
diagnosis) who often are no longer in clinical follow-up.9–20
The ECR is merged on a regular annual basis with civil mu-
nicipal registries to confirm cancer survivors’ vital status and
can be linked at any moment to check current vital status at
any point in time. This is very important, particularly in the
case of longer term survivors for whom such data may not
be readily available via hospital databases. After excluding re-
cently deceased patients, the (former) treating physicians are
asked to verify the patients’ study eligibility (e.g. excluding
patients’ with serious cognitive impairment or who are in
transition to terminal care).
The final selection of cancer patients is then uploaded into
PROFILES, and patients are invited to participate via mail by
their (former) treating physician. The invitation package con-
sists of a letter, a patient information leaflet and a postcard.
The letter explains the goals of the specific study for which
patients are being invited. It includes a link to a secure web-
site, a login name, and a password, so that interested patients
can provide informed consent and complete questionnaires
online. The patient information leaflet contains information
about PROFILES in general. Patients are assured that non-par-
ticipation has no consequences for their treatment or follow-
up care. If the patient does not have access to internet, or pre-
fers written rather than digital communication, (s)he can
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team. Informed consent forms and questionnaires are then
sent by mail within 1 week of receipt of the postcard.
The PROFILES-team actively assists the (former) treating
physicians in mailing the invitation packages. Patients receive
questionnaires between 1 and 4 times a year, depending on
the specific research questions. Patients must be able to read
and write Dutch, and complete a self-report questionnaire
without extensive assistance.
5.2. Normative cohort
PROFILES also contains a reference cohort of approximately
2000 adult individuals from the general Dutch population26
generated by Centerdata (www.centerdata.nl), a research
institute at Tilburg University. This Centerpanel is an online
household panel representative of the Dutch-speaking popu-
lation in the Netherlands. Households without internet ac-
cess are provided with a so-called ‘Net.box’, enabling
connection via a telephone line and a television set. If the
household does not have a television, Centerdata provides
that as well. A professional helpdesk and panel management
support the data collection. Individuals participating in the
Centerpanel are asked to complete a subset of the question-
naires used in PROFILES on an annual basis. This includes
measures of sociodemographics, comorbidity, HRQoL, psy-
chological distress, fatigue, etc. This normative cohort pro-
vides a useful benchmark against which the results based
on cancer survivorship samples can be compared. Impor-
tantly, the normative cohort is large enough to allow extrac-
tion of tailored samples, matched on age, gender and
socioeconomic status, to specific survivorship samples (e.g.
the 2009 response rate was 78%; N = 1731).26
6. Clinical data, sociodemographic data and
patient-reported outcomes
6.1. Clinical data available from the cancer registry
For each patient included in a PROFILES-study, high quality
clinical data are available through the ECR. Since 1955, the
ECR routinely collects data on cancer patient characteristics
and clinical variables such as date of diagnosis, primary
tumour site, TNM tumour classification,27 clinical stage,27 pri-
mary treatment and other primary tumours (second malig-
nancies). Since 1995, the ECR also collects data on comorbid
conditions at time of cancer diagnosis,28 which is unusual
for such cancer registries. In addition, the cancer registry is
increasingly collecting follow-up data such as disease pro-
gression (metastasis and recurrence) from medical record
audits. Finally, linkage of the ECR and the PHARMO Record
Linkage System creates the possibility to study patient centric
drug utilisation, health resources utilisation and their costs,
in addition to the effectiveness and safety of pharmaceuticals
in routine daily practise in cancer patients.29
6.2. Sociodemographic data
Each PROFILES-study uses the same basic set of question-
naires. In addition to questionnaires on patient-reported out-comes, it contains questions on sociodemographics not
routinely collected as part of the ECR. This includes marital sta-
tus, educational level and current occupation. Socioeconomic
status is determined by an indicator developed by Statistics
Netherlands based on individual fiscal data from the year
2000 on the economic value of the home and household in-
come, and provided as aggregate level data for each postal code
(average 17 households),30 which is categorised into tertiles.6.3. Patient-reported outcomes data
National and international comparison of outcome data is of
great importance. Therefore, PROs are assessed using inter-
nationally accepted and validated questionnaires. In all PRO-
FILES-studies, the same basic set of questionnaires is
completed annually to evaluate changes over time. This core
PROFILES dataset can be used to compare different subgroups
of cancer patients (from different PROFILES-studies), and to
compare cancer patients with the normative cohort (with re-
spect to EORTC-QLQ-C30, FAS, HADS, comorbidities and sex-
uality items). In accordance with our objectives to study to
assess patient-reported outcomes of cancer and its treat-
ment, to identifying mediating mechanisms, and to assess
the physical and psychosocial care (needs) of cancer survivors
the basic set of PRO questionnaires includes the following:
– HRQoL of cancer patients will be assessed by the EORCT-
QLQ-C30.31
– Fatigue will be assessed by the Fatigue Assessment Scale
(FAS), which consists of five items reflecting physical fati-
gue and five items reflecting mental fatigue.32
– Anxiety and depression will be assessed by the Hospital
Anxiety and Depression Scale (HADS).33 We will use a score
of 8 as a cut-off value for both depression and anxiety.33,34
– Health care utilisation will be assessed with separate items
(e.g. how often did you visit your general practitioner in the
past 12 months?).12,17
– Health behaviours, including tobacco use, alcohol use and
physical activity will be assessed with separate
questionnaires.
– Comorbidity at the time of the study will be assessed
according to the adapted Self-administered Comorbidity
Questionnaire35 which also assesses the perceived severity
and burden of the comorbid condition.
– The level of information received by cancer patients at dif-
ferent stages of their disease and treatment will be assessed
by the EORTC QLQ-INFO26 questionnaire.36
– For each specific group of cancer survivors, where available,
we include an EORTC condition-specific questionnaire
module (e.g. for breast, lung, colon, and prostate cancer).
The sexuality items from these EORTC modules are also
completed by the control cohort.
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fers the flexibility to add new measures that are relevant to a
specific PROFILES-study, and to add questions that may be-
come relevant as changes take place in treatment (e.g. side-
effects). Cancer treatments are continually being refined,
and toxicity profiles are a moving target.37
7. From data collection to a complete registry:
what does it take?
7.1. High participation rates from physicians
In our previous and ongoing studies, almost all (95%) physi-
cians in our area participate(d). This high participation rate
can be explained by the strong involvement of all physicians
in the survivorship studies, which is established in the active
‘tumour’ working groups. For each specific type of cancer,
multidisciplinary ‘tumour’ working groups meet several
times a year to discuss treatment guidelines and new studies.
The fact that the PROFILES logistics are completely managed
by the PROFILES-team and registration clerks of the ECR
undoubtedly has a positive effect on the willingness of busy
clinicians to participate.
7.2. Ethical issues
When patients agree to take part in a PROFILES-study, they
are asked to sign an informed consent form. By signing and
returning that form (online or by mail), patients consent to
participating in the study and agree to the linkage of the ques-
tionnaire data with the clinical data stored in the ECR. Non-
participation has no consequences on follow-up care or
treatment.
Returned questionnaires do not contain any overt identifi-
ers (i.e. names) but rather are coded by number, for purposes
of data collection tracking and linkage with the ECR database.
Only a few PROFILES-team members have access to a record
that links patient numbers to identifiable information.
A local certified Medical Ethics Committee is required to
approve each study that is conducted using the PROFILES reg-
istry. PROFILES is also registered with the Dutch Data Protec-
tion Authority (registration code 1433221), who supervises the
fair and lawful use and security of personal data collected in
the Netherlands.
7.3. Data entry and retrieval
Online data collection carries with it a number of clear advan-
tages. Patients will complete questionnaires online, and data
are immediately entered into a database. This avoids errors
that can occur when transferring data either manually or
electronically (e.g. scanning) into a database. Missing values
are minimised, as the online system only allows questions
to be skipped if they are of a particular sensitive nature (e.g.
on sexuality). For all other questions, patients are prompted
to respond if left missing.
Patients who prefer a paper-and-pencil based question-
naire will receive a questionnaire by mail. Patients can return
these questionnaires with a prepaid return envelope. The re-
sponses to these questionnaires are scanned, after which acontrol check takes place on that database. Finally, the
scanned database is merged with the web-based database
by the PROFILES panel management system.
7.4. PROFILES helpdesk
The PROFILES registry has a helpdesk that handles patients’
phone calls and emails. The helpdesk answers questions
about the studies that take place using PROFILES, and offers
help with the online questionnaire (e.g. login problems). Pa-
tients can also contact the helpdesk to request a paper-and-
pencil version of the questionnaire. Patients who contact
the helpline with questions of a clinical nature, or who seek
psychosocial support, are referred to either their medical spe-
cialist, their family physician, or to other health care profes-
sionals in their community. To date, only a very small
percentage (±2%) of the patients has contacted the helpdesk.
The helpdesk has access to the panel management system
in order to confirm any changes in information received from
patients or their family members (e.g. change of (email) ad-
dress and wish to discontinue participation). Patients can also
discontinue participation directly via the online panel man-
agement module. Although they are not required to do so, pa-
tients are asked to provide the reason(s) for discontinuing
participation.
7.5. Panel management: cohort retention, non-response
and follow-up
In previous cancer survivorship studies conducted by our re-
search group, high (i.e. P75%) response rates were achieved
when using paper-and-pencil questionnaires.9–20 Several ef-
forts have been made to enhance participation in studies that
are set up using PROFILES. Once a year, a digital newsletter
will be sent to all the participants. This newsletter contains
information on the current status of the different PROFILES-
studies within the registry, study results (new publications
or presentations given) and interviews with researchers,
among others. We keep our website up-to-date by regularly
adding press releases and information on PROFILES presenta-
tions given at (inter-)national conferences. Finally, coopera-
tion of each patient’s (ex)-attending physician and the
PROFILES helpdesk help cohort retention.
Based on other Dutch cohort studies we estimate that a
maximum of 25% of patients will dropout during follow-up.
Non-respondents are sent a reminder letter and a paper-
and-pencil version of the questionnaire within 2 months after
the initial invitation. Mortality rates depend on tumour type
and stage. An important advantage of using the ECR as a sam-
pling frame is that we are able to examine whether selective
response or loss to follow-up occurs, as we have patient, tu-
mour and treatment characteristics of those who do not wish
to participate or who choose to discontinue participation.
7.6. Data storage
The web-based facility is hosted on multi-processor servers
for which infrastructure, configuration, licence, security and
patching are established in accordance with current norms
(NEN-ISO/IEC 27002). Participants log in with their own user
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nicates with a MySQL database located on a different server.
This database server is shielded through a firewall from the
internet and stores the personal data of the participant. Both
PHP and MySQL database servers run Linux as Operating Sys-
tem. Participants fill in their questionnaire on a separate ser-
ver cluster, consisting of Windows 2008 R2 Servers running
BlaiseIS questionnaire software (Statistics Netherlands). The
answers to the questions are stored on a dedicated data stor-
age server, shielded through firewalls from the internet. All
servers are located in a secured room with access only for
authorised personnel. The PROFILES infrastructure and soft-
ware is updated regularly to optimise system operations
and security. Digital PDF-files of questionnaires are stored at
the ECR, which complies with privacy regulations regarding
data collection among cancer patients.
8. Data dissemination
The wealth of medical information from the ECR has always
been available for scientific research, and has resulted in sev-
eral hundred scientific publications written by researchers
from the Netherlands and abroad. The PROFILES registry aims
to provide a national resource for research into the psychoso-
cial well-being of cancer survivors in conjunction with the
ECR and its clinical embedding that builds on high quality
cancer registry data. Therefore, data from PROFILES will be
freely available for non-commercial scientific research, sub-
ject only to privacy and confidentiality restrictions. Data will
be made available through Questacy (DDI 3.x XML) and can
be accessed by our website (www.profilesregistry.nl).38
In order to arrange optimal long-term data warehousing
and dissemination, we follow the quality guidelines that are
formulated in the ‘Data Seal of Approval’ (www.datasealofap-
proval.org) document, developed by Data Archiving and Net-
worked Services. In short, this means that (1) the data can
be found on the internet; (2) research data are accessible
(while taking into account ruling legislation with regard to
personal information and intellectual property of the data);
(3) research data are available in a usable data format; (4) re-
search data are reliable; and (5) research data can be referred
to. Also, PROFILES data will be provided with contextual infor-
mation (metadata). This means that after data collection, the
data will be cleaned, coded and provided with sufficient infor-
mation to enable fellow scientists to access the research data.
Also, we will perform first analyses on the data to check the
quality and validity. After this process, the data will be freely
available for research questions from other non-commercial
groups in the Netherlands and abroad after registration.9. Summary and future perspective
PROFILES is a registry for the study of the physical and psy-
chosocial impact of cancer and its treatment from a dynamic,
growing population-based cohort of cancer survivors.
The linkage of PROs to details of patients’diagnosis and initial
cancer treatment already available through the ECR provides
a unique monitoring system for outcome assessment. This
linkage makes it possible to interpret psychosocial outcomesin relation to medical and demographic characteristics. In
addition, the availability of a control cohort of approximately
2000 persons from the general population who complete the
same basic questionnaire annually provides the opportunity
to estimate the unique impact of cancer, beyond that of nor-
mal ageing and comorbidities.
Currently, PROFILES is a regional project linked to the ECR
covering 2.4 million inhabitants in the Netherlands. In the
nearby future, we foresee to expand the data collection by
use of the PROFILES system to other cancer registries in the
Netherlands or abroad. This will be important for the study
of survivors of relatively rare tumours for which wider cover-
age is necessary in order to achieve sufficient statistical power.
From may 2011 and onwards, raw data from both old and
new PROFILES studies will be made available regularly for
non-commercial scientific research, subject to study ques-
tion, privacy and confidentiality restrictions, and registration
(www.profilesregistry.nl).
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